REFERENCES
- International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–1080.
- Mizushima Y. Revised diagnostic criteria for Behçet’s disease in 1987. Ryumachi. 1988;28:66–70.
- Deuter CME, Kötter I, Wallace GR, et al. Behçet’s disease: ocular effects and treatment. Prog Ret Eye Res. 2008;27:111–136.
- Kacmaz RO, Kempen JH, Newcomb C, et al. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol. 2008;146:828–836.
- Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology. 1999;106:586–589.
- Kötter I, Günaydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Behçet»s disease under cyclosporine A (CSA) than under other medications: results of a retrospective analysis of 117 cases. Clin Rheumatol. 2006;25:482–486.
- Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656–1662.
- Deuter CME, Zierhut M, Möhle A, et al. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheum. 2010;62:2796–2805.
- Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008;146:837–844.
- Krause L, Altenburg A, Pleyer U, et al. Long-term visual prognosis of patients with ocular Adamantiades-Behçet’s disease treated with interferon-α-2a. J Rheumatol. 2008;35:896–903.
- Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behçet’s disease: review and basis for recommendations. Rheumatology. 2007;46:736–741.
- Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–1368.